BPC-157 Monitoring for Adults Ages 50 to 64: What Clinicians and Patients Need to Know

HealthRX.com

No monitoring schedule exists yet for older adults

Print or save as PDF

See the public record for BPC-157

  • Approval status / Not FDA-approved; no approved product found in any country FDA searched [1]
  • Human safety data / FDA: insufficient clinical safety information to characterize the safety profile [1]
  • Human pharmacokinetics / None found for oral, subcutaneous, nasal or skin use [1]
  • Checked in a human study / Blood work and vital signs before and after each infusion, repeated on following days, in 2 adults aged 58 and 68 [3]
  • Animal signals / aPTT, ALT, glucose and triglycerides shifted in 28-day studies [1]
  • Sport status / WADA S0, prohibited at all times [4]

What was measured in people

In a two-person intravenous study, researchers took baseline blood work and vital signs, infused 10 mg of BPC-157 on day 1 and 20 mg on day 2, then repeated fasting blood work and vital signs on the following days. One participant was a 58-year-old man and the other a 68-year-old woman [3]. The tested heart, liver, kidney, thyroid and glucose markers showed no measurable change, and no side effects were reported [3]. Two people cannot support a safety conclusion.

A single-arm pilot injected a total of 10 mg around the bladder wall in 12 women aged 39 to 76 whose interstitial cystitis had not responded to pentosan polysulfate; 10 of 12 reported complete symptom resolution and 2 of 12 about 80%, with no adverse events reported [5]. A retrospective chart review at one Florida clinic included 17 patients given BPC-157 into the knee, alone or with thymosin beta-4 (16 were reached by phone); 11 of 12 who received BPC-157 alone reported significant improvement, with no control group and no validated outcome tools [6].

None of these studies [3][5][6] sets a monitoring schedule for adults ages 50 to 64, and the systematic review concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [2].

Questions worth asking

Choose the questions you want to keep

What the animal studies showed

In 28-day intramuscular toxicity studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels [1]. Longer studies and cancer-risk studies were not available [1]. FDA also noted that the reported protective effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials, that the molecular targets have not been identified, and that dose-response relationships for those effects were not established [1].

What has been reported as harm in people

FDA's search of its adverse-event database through December 4, 2025 found 3 reports, all for injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used a compounded thymosin product; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 research product [1]. FDA said it cannot tell whether BPC-157 caused any of them [1].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short and small; in the healthy-volunteer enema studies the most frequent events were headache and flatulence [1]. FDA concluded there is insufficient clinical safety information to characterize the safety profile, and found no human studies of BPC-157 given by mouth, by subcutaneous injection, as a nasal spray or on the skin [1].

What is its regulatory status?

FDA's July 2026 review found no approved product containing BPC-157 in any country it searched, and its reviewers recommended against adding it to the pharmacy bulks list [1]. A July 23, 2026 advisory committee vote favoring its addition is advice only; BPC-157 is not on the list [7][8]. A draft HHS enforcement-discretion policy announced October 28, 2026 is not an approval and does not put BPC-157 on any list [9]. WADA names BPC-157 in S0, prohibited at all times [4].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, what is the regulatory status of BPC-157 for adults ages 50 to 64?

Question 1 of 3

Score: 0 right, 0 of 3 answered

What has been checked in people given BPC-157 at around age 55?
No monitoring recommendation exists. In a two-person intravenous study with participants aged 58 and 68, researchers took blood work and vital signs before and after each infusion and repeated fasting blood work on the following days [3]. In animal studies, clotting time, ALT, glucose and triglycerides shifted [1].
Is BPC-157 FDA-approved for anything?
No. No FDA-approved drug contains BPC-157, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].
Could BPC-157 interact with a statin or a blood thinner?
FDA found no human pharmacokinetic data for BPC-157 given orally, subcutaneously, nasally or on the skin [1]. In 28-day animal studies BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs [1].
Is BPC-157 allowed in sport?
WADA names BPC-157 in S0, the non-approved substances class, and it is prohibited at all times, in and out of competition [4].
Show all 9 referencesHide references
Evidence overview for BPC-157 Monitoring for Adults Ages 50 to 64: What Clinicians and Patients Need to Know